EU-HTA's 2026 Scientific Consultation Window: Can Pharma Fix
Tomorrow's PICO Problems Before Phase III?
Europe’s pharmaceutical evidence landscape is changing. Under the EU Health Technology Assessment (HTA) Regulation, generating strong clinical evidence is no longer sufficient on its own. Pharmaceutical companies must also consider whether their clinical development programmes will address the comparative evidence needs of European HTA authorities.
With the European Commission’s latest Joint Scientific Consultation (JSC) application window open from 23 September to 21 October 2026, pharmaceutical manufacturers have a timely opportunity to rethink how early evidence planning influences future Joint Clinical Assessments (JCAs).
The critical question is: Can pharmaceutical companies identify and address tomorrow’s PICO challenges before pivotal Phase III trials are finalised?
Why PICO Alignment Is Becoming a Strategic Priority
At the centre of the EU-HTA framework is PICO: Population, Intervention, Comparator and Outcomes.
Although PICO is a familiar concept in clinical research, its implications for European Market Access are increasingly significant.
A clinical trial designed primarily to satisfy regulatory requirements may not fully address the comparative effectiveness questions raised during a JCA.
For example, a pharmaceutical manufacturer might select a placebo or established treatment as its primary comparator, while HTA authorities require comparisons against different standards of care used across European healthcare systems.
Similarly, differences in patient subgroups, clinical endpoints and treatment pathways may create evidence gaps that become difficult to resolve after pivotal studies have been completed.
The challenge is not simply generating more evidence. It is generating the right evidence early enough to support regulatory and HTA expectations.
Joint Scientific Consultation: An Opportunity to Address Evidence Gaps Earlier
The EU-HTA Regulation provides a mechanism through which health technology developers can seek scientific consultation on clinical development plans and evidence requirements for future JCAs.
The current application period, running until 21 October 2026, offers eligible developers an opportunity to request consultation before critical development decisions become difficult or costly to change.
According to the European Commission, the available consultation schedules include briefing document deadlines in January, February and March 2027, followed by discussion meetings beginning in April, May and June 2027.
This creates an opportunity for manufacturers to examine important questions:
Are the selected trial comparators relevant to future European HTA assessments?
Will the planned endpoints demonstrate meaningful relative clinical effectiveness?
Could differences in patient populations create additional evidence requirements?
What supplementary evidence might be needed to address anticipated PICO scenarios?
Joint Scientific Consultation does not guarantee favourable future assessment outcomes. However, it can help developers better understand evidence expectations while clinical development strategies can still be refined.
Can Real-World Evidence Help Bridge the Remaining Gaps?
Even with early scientific consultation, pharmaceutical companies may face evidence gaps that cannot be fully addressed through randomised controlled trials.
This is where Real-World Evidence (RWE) and advanced comparative effectiveness methodologies may become increasingly relevant.
Target-trial emulation, external control arms and observational comparative studies can potentially support evidence generation where direct randomised comparisons are unavailable.
Similarly, methodologies such as Network Meta-Analysis (NMA), Matching-Adjusted Indirect Comparison (MAIC) and Simulated Treatment Comparison (STC) may help address certain comparator-related evidence gaps.
However, these approaches introduce methodological challenges involving confounding, population differences, treatment-effect modifiers and uncertainty.
Their suitability depends on the available data, the assumptions required and the specific assessment question.
For Market Access and HEOR teams, the strategic priority is therefore to anticipate where supplementary evidence may be needed rather than waiting until the JCA dossier is being prepared.
From Regulatory Development to Integrated Market Access Strategy
The changing European HTA environment also raises an important organisational question: When should Market Access and HEOR teams become involved in clinical development decisions?
Traditionally, regulatory, clinical development and Market Access functions have often operated with different evidence priorities.
Under the EU-HTA framework, closer collaboration may become essential.
Clinical development teams must consider future comparative effectiveness questions. HEOR specialists need to anticipate evidence limitations and analytical requirements. Market Access teams must understand how EU-level assessments interact with national reimbursement expectations.
Early cross-functional collaboration can help companies build a more coherent evidence-generation strategy across the product lifecycle.
The companies best prepared for future JCAs may be those that treat HTA readiness as an early development responsibility rather than a late-stage submission exercise.
The Bigger Question for European Pharma
The 2026 Joint Scientific Consultation window highlights a broader transformation in pharmaceutical evidence planning.
The conversation is moving beyond whether a treatment demonstrates clinical benefit towards whether the available evidence can support multiple comparative assessment questions across Europe.
For pharmaceutical manufacturers, this raises a strategic choice: continue addressing HTA evidence gaps after clinical development, or anticipate those requirements before pivotal trial designs are finalised.
Early consultation cannot eliminate every uncertainty, but it offers an important opportunity to improve alignment between clinical research, evidence generation and future Market Access requirements.
Continue the Discussion at the European RWE & Market Access Summit 2026
These evolving challenges will be central to discussions at the European RWE & Market Access Summit 2026 – JCA & PICO Strategy Edition, taking place on 21–22 October 2026 at Inntel Hotels Amsterdam Landmark, Amsterdam, Netherlands.
Bringing together senior professionals from pharmaceutical and biopharmaceutical companies, HEOR, Real-World Evidence, Market Access, HTA and evidence-generation organisations, the summit will explore:
EU-HTA and JCA readiness: Navigating emerging evidence requirements and PICO alignment challenges.
Advanced RWE methodologies: Target-trial emulation, external controls and comparative effectiveness research.
Evidence synthesis and uncertainty: Addressing methodological challenges through NMA, MAIC and STC.
European Market Access strategy: Connecting EU-level clinical assessments with national payer and reimbursement expectations.
AI-enabled evidence generation: Exploring the evolving role of artificial intelligence in RWE and HTA.
As the current JSC application window closes on the summit’s opening day, the timing offers an especially relevant opportunity for industry stakeholders to exchange perspectives on the future of European evidence strategy.
Join the conversation in Amsterdam and explore how the next generation of clinical evidence strategies can support stronger HTA readiness and informed Market Access decisions.
Event: European RWE & Market Access Summit 2026
Date: 21–22 October 2026
Venue: Inntel Hotels Amsterdam Landmark, Netherlands
Visit here : https://wlcus.com/event/rwe_market_access_event_2026/
Click here to Register: https://wlcus.com/event/rwe_market_access_event_2026/#Registration